11,389 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by DGS Capital Management LLC

DGS Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,389 shares of the company’s stock, valued at approximately $119,000.

Several other institutional investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its position in shares of Teva Pharmaceutical Industries by 705.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock worth $6,051,000 after acquiring an additional 507,568 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth about $3,000,000. SG Americas Securities LLC raised its position in Teva Pharmaceutical Industries by 31.7% in the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after purchasing an additional 131,043 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Teva Pharmaceutical Industries by 42.2% in the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock valued at $3,515,000 after buying an additional 102,261 shares during the period. Finally, Gateway Investment Advisers LLC grew its position in shares of Teva Pharmaceutical Industries by 28.6% during the fourth quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock worth $437,000 after buying an additional 9,312 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the transaction, the chief accounting officer now owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the sale, the executive vice president now directly owns 382,590 shares of the company’s stock, valued at $5,172,616.80. The disclosure for this sale can be found here. Insiders have sold 390,738 shares of company stock valued at $5,132,766 in the last ninety days. 0.62% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Up 0.8 %

TEVA opened at $13.19 on Thursday. Teva Pharmaceutical Industries Limited has a one year low of $7.09 and a one year high of $14.47. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The stock has a market capitalization of $14.79 billion, a P/E ratio of -28.06, a price-to-earnings-growth ratio of 1.57 and a beta of 1.05. The business’s 50-day simple moving average is $13.45 and its 200-day simple moving average is $11.21.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The firm had revenue of $4.46 billion for the quarter, compared to the consensus estimate of $3.97 billion. Analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TEVA shares. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a report on Friday, March 8th. Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. The Goldman Sachs Group increased their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Barclays lifted their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Finally, Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their price objective for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $13.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.